JPMorgan raised the firm’s price target on Progyny (PGNY) to $25 from $23 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny’s Cautious Optimism Amid Challenges: A Hold Rating Analysis
- Progyny price target raised to $23 from $21 at Canaccord
- Progyny’s Earnings Call Highlights Robust Growth and Strategic Partnerships
- Strong Financial Performance and Market Trends Support Buy Rating for Progyny
- Progyny, Inc. Reports Record Q2 2025 Revenue